Sangamo Therapeutics, Inc.
NASDAQ:SGMOBiotechnology
+$0.00 today
- Market cap
- $70.43M
- Beta
- 1.29
- P/E (TTM)
- -0.5
- EPS (TTM)
- -$0.32
Volume 0.61M
Average 9.53M
SGMO Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Sangamo Therapeutics, Inc.NASDAQ: SGMO
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity turns negative
Q1 FY2026 total equity was -$18.96M, compared with $4.91M a year earlier.
Context
- Total equity amounted to 31.6% of total assets at the end of Q1 FY2026, up 25.9 pp from a year earlier.
- Total equity increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -486.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- (14.27M) USD
- Year-over-year change
- -162.7%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (14.27M) | -162.7% |
| FY2024 | 2024-12-31 | 22.77M | -72.5% |
| FY2023 | 2023-12-31 | 82.89M | -71.9% |
| FY2022 | 2022-12-31 | 294.96M | -21.4% |
| FY2021 | 2021-12-31 | 375.34M | — |
Total Equity vs competitors
How SGMO compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -486.4% is the lowest of 11, against a peer median of -8.4%.
- Total equity amounts to 31.6% of total assets for SGMO, versus a peer median of 69.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $262.65M USD | -4.0% | -7.9% | 89.4% | |
| Mar 2026 | $234.25M USD | +20.0% | -3.9% | 71.2% | |
| Mar 2026 | $203.05M USD | +275.0% | -12.1% | 84.0% | |
| Mar 2026 | CHF 68.25M CHF | -46.8% | -30.1% | 78.1% | |
| Mar 2026 | $43.23M USD | -12.9% | -29.6% | 33.4% | |
| Mar 2026 | $36.05M USD | +688.7% | -14.3% | 18.6% | |
| Mar 2026 | $35.54M USD | +764.5% | -17.5% | 68.5% | |
IMDXInsight Molecular Diagnostics Inc. | Mar 2026 | -$10.69M USD | -204.6% | — | 26.4% |
| Mar 2026 | -$18.96M USD | -486.4% | — | 31.6% | |
| Dec 2025 | -€21.69M EUR | -345.6% | — | 34.6% | |
| Mar 2026 | -$311.59M USD | -479.3% | — | 446.4% | |
| Peer median (excluding SGMO) | — | -8.4% | -14.3% | 69.9% | |
Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 178.87M | 100.44M | 45.2M | 41.92M | 20.95M |
| Short-term Investments | 197.68M | 177.19M | 35.8M | 0 | 0 |
| Net Receivables | 6.36M | 4.47M | 4.07M | 4.6M | 10.51M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 9.26M | 5.18M | 4.37M |
| Total Current Assets | 398.77M | 300.33M | 94.33M | 51.69M | 35.83M |
| Property, Plant & Equipment (Net) | 124.7M | 125.53M | 52.87M | 34.76M | 14.11M |
| Goodwill | 39.7M | 37.55M | 0 | 0 | 0 |
| Intangible Assets | 53.76M | 50.73M | 0 | 0 | 0 |
| Long-term Investments | 88.17M | 29.85M | 1.5M | 1.5M | 0 |
| Tax Assets | 0 | 6.27M | 0 | 0 | 0 |
| Other Non-current Assets | 16.82M | 12.25M | 16.63M | 13.69M | 9.81M |
| Total Non-current Assets | 323.15M | 262.18M | 70.99M | 49.94M | 23.92M |
| Total Assets | 721.92M | 562.51M | 165.32M | 101.64M | 59.75M |
| Account Payables | 9.76M | 22.42M | 15.26M | 15.49M | 14.44M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 4.07M | 10.14M |
| Deferred Revenue | 85.71M | 51.78M | 0 | 7.56M | 899K |
| Other Current Liabilities | 20.84M | 11.89M | 11.73M | 14.57M | 17.72M |
| Total Current Liabilities | 127.89M | 111.71M | 47.73M | 45.81M | 42.47M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 6.65M | 6.27M | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 166.78M | 109.38M | 0 | 5.87M | 5.87M |
| Other Non-current Liabilities | 1.22M | 1.21M | 1.19M | 933K | 580K |
| Total Non-current Liabilities | 218.69M | 155.84M | 34.7M | 33.06M | 31.55M |
| Total Liabilities | 346.58M | 267.55M | 82.43M | 78.87M | 74.01M |
| Common Stock | 1.46M | 1.67M | 1.78M | 2.13M | 3.51M |
| Retained Earnings | (956.27M) | (1.15B) | (1.41B) | (1.5B) | (1.63B) |
| Accumulated OCI | (3.99M) | (8.4M) | (4.6M) | (7.53M) | (1.46M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 375.34M | 294.96M | 82.89M | 22.77M | (14.27M) |
| Total Debt | 48.08M | 43.11M | 38.1M | 30.57M | 26.8M |
| Net Debt | (130.79M) | (57.34M) | (7.1M) | (11.35M) | 5.85M |
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
Intrinsic Alpha fair value
Locked
Current Price
$0.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.